Brain Health & Nootropics
Cerebrolysin
← Back to Library
Limited / unverified Limited / unverified Limited / unverified Neural Repair
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous, Intramuscular
Typical vial sizes: 10, 20 mg
Dosing window: Morning
Receptor / target: BDNF; NGF; GDNF; CNTF
Properties: Not stated
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-30 | 5mg 1x daily | Administer 5 days per week for 30 days. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative Titration
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 20 mg 1x daily | Loading phase. |
| Week 2 | 24 mg daily | Split: 12mg AM + 12mg PM. |
| Week 3 | 28 mg daily | Split: 14mg AM + 14mg PM. |
| Weeks 4-6 | 32 mg daily | Split: 16mg AM + 16mg PM. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Nootropic protocols are state-dependent: sleep, anxiety, stimulants, psychiatric history, and route can change the response. The logic is morning-biased, low-entry dosing, and stopping if arousal or mood destabilizes. Entry context: target (BDNF; NGF; GDNF; CNTF); route Subcutaneous/Intramuscular; timing Morning. Limited-evidence dosing tables are hypotheses, not recommendations.
Independent evidence
Independent safety notes: No independent approved-label regimen is listed for this entry. Dosing notes remain unverified.
Regulatory status: no approved label identified
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Severe renal impairment: the free amino acid component of Cerebrolysin (75% of the preparation) places a nitrogen load on renal clearance pathways; in subjects with severely reduced GFR, amino acid accumulation and metabolic byproduct buildup is a meaningful concern. Limited / unverified
- Epilepsy or active seizure disorders: Cerebrolysin has been associated with lowering the seizure threshold in susceptible individuals through its neurostimulatory and glutamatergic modulatory activity; contraindicated in subjects with uncontrolled seizure disorders. Limited / unverified
- Active status epilepticus: absolute contraindication. Limited / unverified
- Known hypersensitivity to porcine-derived biological products: Cerebrolysin is derived from porcine brain; subjects with pork allergies or hypersensitivity to porcine proteins carry a risk of allergic reaction ranging from injection site reaction to systemic anaphylaxis. Limited / unverified
- Active malignancy involving the CNS: neurotrophic growth factor activity (NGF, BDNF, GDNF) from Cerebrolysin could theoretically support tumor cell survival and proliferation in brain tumors expressing Trk receptors. Limited / unverified
- Pregnancy: no clinical safety data; neurotrophic factor delivery during CNS development has not been established as safe. Limited / unverified
- Breastfeeding: no safety data. Limited / unverified
- Concurrent use with MAO inhibitors: potential pharmacodynamic interaction through serotonergic and noradrenergic modulation. Limited / unverified
- Acute stroke during the hyperacute phase (first 4-6 hours): Cerebrolysin clinical protocols specify administration after the hyperacute window; early intervention timing is a clinical judgment requiring medical supervision. Limited / unverified
Side effects (limited evidence)
- Injection site soreness: the primary and most consistent adverse effect with IM administration; larger volume injections into muscle produce mechanical distension and mild inflammatory response; more pronounced with higher doses (20-32mg/day split IM); typically resolves within 24-48 hours. Limited / unverified
- Mild flu-like symptoms: low-grade fever, malaise, mild chills; reported in a subset of users during the first 1-2 weeks of a new cycle; likely related to the immune response to the porcine-derived biological extract; typically self-limiting. Limited / unverified
- Dizziness and lightheadedness: uncommon; reported in subjects receiving higher doses; mechanism not fully characterized; mild and transient. Limited / unverified
- Nausea: mild; reported in a small subset; more common with faster injection rates; slow administration mitigates. Limited / unverified
- Headache: uncommon; reported in the initial days; may reflect the rapid changes in neurotrophic factor signaling in cerebrovascular and neural tissue. Limited / unverified
- Agitation or restlessness: paradoxical stimulant-like response in a small subset of users; the NGF-mediated cholinergic activation in some subjects produces heightened arousal rather than cognitive clarity; usually resolves within the first week. Limited / unverified
- Allergic reactions: ranging from local injection site erythema and urticaria to (rarely) systemic allergic responses in porcine-sensitive subjects; the porcine biological origin is the source of this risk. Limited / unverified
- Potential seizure threshold lowering: the primary serious adverse effect documented in clinical trial safety data; most relevant in subjects with pre-existing epileptiform activity; routine use in healthy subjects at standard doses is not associated with seizure induction. Limited / unverified
- Insomnia: reported by a minority of subjects with morning IM or subcutaneous dosing, particularly at higher doses; related to neurostimulatory NGF/BDNF activation of arousal circuits; manage with strict morning administration. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.